In addition, melanoma patients with high TMB and the CD16-V158F polymorphism (conferring higher binding affinity to IgG1 antibodies) had higher response rates than all the other patients, suggesting that FcγR+ myeloid cells in the tumor might contribute to the anti-tumor activity of Ipilimumab through ADCC-dependent Treg depletion (129). Here, FCGR2A is linked to neoplasm.